One Case of Acute Exacerbation of Chronic Renal Failure in a Patient with Drug Hypersensitivity Syndrome Induced by Allopurinol Sustained-Release Capsules

doi:10.19803/j.1672-8629.20250024

Abstract

Abstract: Objective To study one case of drug hypersensitivity syndrome caused by allopurinol sustained-release capsules so as to provide a reference for safe clinical medications. Methods The diagnosis and treatment process of an adult patient who developed drug hypersensitivity syndrome and acute exacerbation of chronic renal failure one month after using allopurinol sustained-release capsules was analyzed. Based on related literature, the characteristics of the case and the mechanisms of the drug for adverse reactions were analyzed before treatment for this patient was traced. Results Following a causality assessment, the drug hypersensitivity syndrome was attributed to allopurinol. The patient's condition was stabilized after discontinuation of medication and symptomatic treatment. Conclusion Patients with chronic renal failure who use allopurinol sustained-release capsules may develop drug hypersensitivity syndrome, potentially leading to acute deterioration of renal function. Therefore, enhanced monitoring of adverse reactions is required during treatment. HLA-B*5801 genetic testing may help reduce the risk of adverse reactions.

Key words: Allopurinol, Drug Hypersensitivity Syndrome, Renal Failure, Adverse Drug Reaction, HLA-B*5801

CLC Number:

R977
R994.11

QI Qige, WU Di. One Case of Acute Exacerbation of Chronic Renal Failure in a Patient with Drug Hypersensitivity Syndrome Induced by Allopurinol Sustained-Release Capsules[J]. Chinese Journal of Pharmacovigilance, 2025, 22(12): 1431-1433.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20250024

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I12/1431

References

[1] Chinese Society of Endocrinology. Chinese Medical Association. Guideline for the Diagnosis and Management of Hyperuricemia and Gout in China(2019)[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志), 2020, 36(1): 1-13.
[2] SUN JM, XIA Q, YANG PP, et al.Characteristics and Evaluations of Different Diagnostic Criteria for Drug-Induced Hypersensitivity Syndrome: a Report of 75 Cases[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2024, 44(18): 2154-2158.
[3] KOLLER E, DIXIT N, LEE R, et al.A Case of Allopurinol-Induced Drug Reaction with Eosinophilia and Systemic Symptoms in a Patient with Polycystic Kidney Disease and Chronic Kidney Disease[J]. World Medical Journal, 2025, 124(2): 169-172.
[4] MĄSIOR MN, ROSTKOWSKA OM, FURMAŃCZYK-ZAWISKA A, et al. DRESS Syndrome: Renal Involvement in Two Cases-a Comprehensive Analysis and Literature Review of Improved Diagnosis and Treatment[J]. The American Journal of Case Reports, 2024, 25: e942315.
[5] SETOYAMA A, SAWADA Y.Drug-Induced Hypersensitivity Syndrome Accompanied with Acute Renal Failure with Hemodialysis: a Case Report and Literature Review[J]. Cureus, 2024, 16(1): e52335.
[6] CHEN IH, KUO MC, HWANG SJ, et al.Allopurinol-Induced Severe Hypersensitivity with Acute Renal Failure[J]. The Kaohsiung Journal of Medical Sciences, 2005, 21(5): 228-232.
[7] LIU Q, HOU W, SHEN Y, et al.Allopurinol-Induced Acute Kidney Injury and DRESS Syndrome without Eosinophilia: a Case Report[J]. Clinical Nephrology, 2021, 96(3): 188-190.
[8] DAGNON DSM, DOMINGUES SM, OLUIC S, et al.Renal Manifest-ations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: a Systematic Review of 71 Cases[J]. Journal of Clinical Medicine, 2023, 12(14): 4576.
[9] ESPOSITO AJ, MURPHY RC, TOUKATLY MN, et al.Acute Kidney Injury in Allopurinol-Induced DRESS Syndrome: a Case Report of Concurrent Tubulointerstitial Nephritis and Kidney-Limited Necrotizing Vasculitis[J]. Clinical Nephrology, 2017, 87(6): 316-319.
[10] ZHENG FY, WU Y, RAO YF, et al.The Role and Case Analysis of Naranjo's Scale in the Evaluation of Adverse Drug Reactions[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2012, 47(8): 650-652.
[11] GONG J, XIANG Q, WHANG ZN, et al.Individualized Medication Clinical Research Analysis of Allopurinol Based on HLA-B Gene Polymorphism[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2022, 38(10): 1133-1136.
[12] FITZGERALD JD, DALBETH N, MIKULS T, et al.2020 American College of Rheumatology Guideline for the Management of Gout[J]. Arthritis Rheumatol, 2020, 72(6): 879-895.
[13] PAN X, XIE P, CHANG H, et al.Would Allopurinol Hypersensitivity Syndrome be a Turning Point of CKD?[J]. Immunological Journal(免疫学杂志), 2022, 38(1): 88-92.
[14] YASEEN W, AUGUSTE B, ZIPURSKY J.Allopurinol Hypersen-sitivity Syndrome[J]. Canadian Medical Association Journal, 2023, 195(13): E483.
[15] LI HH.Clinical Analysis of 65 Patients with Severe Adverse Drug Reactions[D]. Shandong: Shandong University, 2023.
[16] HAMA N, ABE R, GIBSON A, et al.Drug-Induced Hypersensitivity Syndrome(DIHS)/Drug Reaction with Eosinophilia and Systemic Symptoms(DRESS): Clinical Features and Pathogenesis[J]. The Journal of Allergy and Clinical Immunology, 2022, 10(5): 1155-1167.
[17] STIRTON H, SHEAR NH, DODIUK-GAD RP.Drug Reaction with Eosinophilia and Systemic Symptoms(DReSS)/ Drug-Induced Hypersensitivity Syndrome(DiHS)-Readdressing the DReSS[J]. Biomedicines, 2022, 10(5): 999.
[18] WEI BM, FOX LP, KAFFENBERGER BH, et al.Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. Part I. Epidemiology, Pathogenesis, Clinicopathological Features, and Prognosis[J]. Journal of the American Academy of Dermatology, 2024, 90(5): 885-908.
[19] CAO JL, XING XZ, FAN J, et al.Advances in the Pathogenesis and Prognosis of Drug-Induced Hypersensitivity Syndrome[J]. Journal of Practical Dermatology(实用皮肤病学杂志), 2024, 17(2): 93-96, 106.